Analyzing Castle Biosciences (CSTL) and The Competition
Castle Biosciences (NASDAQ: CSTL) is one of 29 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare Castle Biosciences to similar businesses based on the strength of its risk, analyst recommendations, valuation, institutional ownership, dividends, earnings and profitability.
Insider & Institutional Ownership
29.7% of Castle Biosciences shares are held by institutional investors. Comparatively, 51.0% of shares of all “Medical laboratories” companies are held by institutional investors. 14.2% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current ratings and recommmendations for Castle Biosciences and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Castle Biosciences Competitors||236||800||979||71||2.42|
Castle Biosciences currently has a consensus price target of $40.00, suggesting a potential upside of 51.11%. As a group, “Medical laboratories” companies have a potential upside of 64.43%. Given Castle Biosciences’ rivals higher possible upside, analysts plainly believe Castle Biosciences has less favorable growth aspects than its rivals.
This table compares Castle Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Castle Biosciences Competitors||-124.53%||-81.24%||-29.48%|
Earnings and Valuation
This table compares Castle Biosciences and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Castle Biosciences||$51.87 million||$5.28 million||-32.68|
|Castle Biosciences Competitors||$1.03 billion||$53.91 million||29.99|
Castle Biosciences’ rivals have higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Castle Biosciences rivals beat Castle Biosciences on 7 of the 12 factors compared.
About Castle Biosciences
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.